We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Prototype Test Developed for Ocular Trachoma

By LabMedica International staff writers
Posted on 15 Aug 2011
An evaluation has been made of a prototype point-of-care (POC) test, developed for field diagnosis of ocular Chlamydia trachomatis, in low prevalence settings. More...


The clinical signs of active trachoma are often present in the absence of ocular C. trachomatis infection in low prevalence and mass treated settings and treatment decisions are currently based on the prevalence of clinical signs.

A simple point-of-care (POC) test has been compared in laboratory testing for C. trachomatis infection to a polymerase chain reaction (PCR) which is highly sensitive but expensive and requires well-trained staff. Scientists from the London School of Hygiene and Tropical Medicine, (London, UK), working with others in the Gambia and Sengal screened children under the age of 10 for signs of trachoma. Two ocular swabs were taken from the right eye. The first swab was tested by the POC test in the field. This assay detects the chlamydial lipopolysaccharide (LPS), using lateral flow technology and this assay was designed specifically for use in resource-limited settings, and therefore has no electricity, water, or laboratory equipment requirements. The second swab was tested for the presence of C. trachomatis by Amplicor PCR.

A total of 3,734 children were screened, 950 in the first and 1,171 in the second Gambian study, and 1,613 in Senegal. The sensitivity of the prototype POC test (Diagnostics Development Unit, University of Cambridge, UK), ranged between 33.3% and 67.9%, the specificity was between 92.4% and 99.0%. The positive predictive value ranged between 4.3% and 21.0%, and the negative predictive value was between 98.0% and 99.8%. The rate of false-positives increased markedly at temperatures above 31.4 °C and relative humidities below 11.4%.

Although the POC test is a qualitative assay, the signal strength was scored on a scale from a weak 0.5 to a strong 5.0 in the field. There was a significant association between increased organism load and increased POC test signal strength. The Amplicor Chlamydia trachomatis PCR assay is a product of Roche Diagnostics (Burgess Hill, UK).

The authors concluded that the in its present format, this prototype POC test is not suitable for field diagnosis of ocular C. trachomatis as its specificity decreases in hot and dry conditions. In the absence of a suitable test for infection, trachoma diagnosis remains dependent on clinical signs and this will likely result in the unnecessary distribution of mass antibiotic treatment. The study was published on in the online journal Public Library of Science Neglected Tropical Diseases.

Related Links:
London School of Hygiene and Tropical Medicine
University of Cambridge
Roche diagnostics




New
Gold Member
Hematology Analyzer
Medonic M32B
Serological Pipet Controller
PIPETBOY GENIUS
New
Alcohol Testing Device
Dräger Alcotest 7000
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: A diagnostic test can distinguish patients with head and neck squamous cell carcinoma who can be cured with surgery alone (Photo courtesy of University of Turku)

Novel Diagnostic Tool to Revolutionize Treatment Guidance of Head and Neck Cancer

Head and neck squamous cell carcinoma (HNSCC) is a solid tumor type commonly treated with surgery. However, there has been no clinically available method to determine which patients can be cured with surgery... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Pathology

view channel
Image: The smart microscope can predict the onset of misfolded protein aggregation, a hallmark of neurodegenerative diseases (Photo courtesy of EPFL)

Self-Driving Microscope Tracks and Analyzes Misfolded Protein Aggregation in Real Time

The accumulation of misfolded proteins in the brain is central to the progression of neurodegenerative diseases like Huntington’s, Alzheimer’s, and Parkinson’s. Yet to the human eye, proteins that are... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.